Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals (NASDAQ: SNDX) announced inducement equity awards granted on February 1, 2026 under its 2023 Inducement Plan.

Rhea-AI Summary

Syndax Pharmaceuticals (NASDAQ: SNDX) announced inducement equity awards granted on February 1, 2026 under its 2023 Inducement Plan. The company granted options to purchase up to 11,600 shares to two new employees.

The options vest over four years: 25% after one year and the remainder monthly (1/48th) over the following 36 months, subject to continued service.

Argus Feb 5 session

-1.37% close to close Open Argus

Details

News Market Reaction – SNDX

In the Feb 5 session, SNDX declined 1.37%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a small inducement grant of 11,600 stock options under the 2023 Inducement...

Analysis

This announcement details a small inducement grant of 11,600 stock options under the 2023 Inducement Plan, vesting over 4 years per NASDAQ Listing Rule 5635(c)(4). In context, SNDX shares traded above the $14.79 200-day MA and within 6.51% of the 52-week high, following recent updates on revenues, access programs, and clinical data. Investors may monitor future hiring- and compensation-related disclosures alongside upcoming financial and clinical milestones.

Key Figures

Inducement options granted: 11,600 shares Grant date: February 1, 2026 Vesting period: 4 years +5 more

Inducement options granted

11,600 shares

Stock options to two new employees under 2023 Inducement Plan

Grant date

February 1, 2026

Date options were granted as inducement awards

Vesting period

4 years

Total vesting duration for the stock options

Initial vesting tranche

25%

Vests on one-year anniversary of vesting commencement date

Subsequent vesting schedule

1/48th monthly

Monthly vesting over remaining 36 months after first anniversary

Remaining vesting duration

36 months

Monthly vesting period following initial 25% cliff

Number of employees

2 employees

Recipients of the inducement stock option awards

Plan name

2023 Inducement Plan

Equity plan under which these options were granted

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Prelim 2025 results

   24h Move

   -1.3%

   Preliminary 4Q25 and 2025 revenue, cash and 2026 expense outlook disclosed.

2. Jan 07

   Access program deal

   24h Move

   +8.7%

   Managed Access Program with WODA to expand Revuforj access internationally.

3. Jan 05

   Conference presentation

   24h Move

   -5.1%

   Announcement of CEO presentation slot at J.P. Morgan Healthcare Conference.

4. Dec 12

   Drug award news

   24h Move

   -0.2%

   Revuforj named Best New Drug at Scrip Awards 2025 after recent approvals.

5. Dec 08

   Clinical data update

   24h Move

   -1.7%

   Multiple strong Revuforj datasets presented at ASH 2025 across leukemia settings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

NASDAQ Listing Rule 5635(c)(4)

1 terms

NASDAQ Listing Rule 5635(c)(4) regulatory

"Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February 1, 2026, the Company granted inducement awards to purchase up to 11,600 shares of common stock to two new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did Syndax (SNDX) announce on February 1, 2026?

Syndax granted inducement stock options to two new employees to purchase up to 11,600 shares. According to the company, the awards were made under the 2023 Inducement Plan and are intended as hiring incentives for new hires.

How do the Syndax (SNDX) inducement stock options vest and over what timeline?

The options vest over four years with 25% vesting after one year, then monthly thereafter. According to the company, the remaining shares vest at 1/48th per month over the subsequent 36 months, subject to continued service.

How many employees received inducement awards from Syndax (SNDX) on February 1, 2026?

Two new employees received inducement awards to purchase up to 11,600 shares in total. According to the company, the grants were issued under the 2023 Inducement Plan as hiring-related equity awards.

Do the Syndax (SNDX) inducement awards dilute existing shareholders immediately?

The awards potentially increase outstanding shares if options are exercised, but do not dilute immediately upon grant. According to the company, dilution would occur only when and if the stock options are exercised by the employees.

Under which plan were the Syndax (SNDX) inducement awards issued and why does it matter?

The awards were issued under the company's 2023 Inducement Plan, which governs new-hire equity grants. According to the company, using the inducement plan allows issuance outside existing equity plans to incentivize new employees.